1. Introduction {#s0005}
===============

Alzheimer\'s disease (AD) is the most common form of dementia, which was characterized clinically by progressive memory and other cognitive abilities decline. At the neuropathological level, AD neuropathological accumulation begins years before the onset of dementia ([@bb0355]) and develops in a specific temporal-ordered manner ([@bb0320]), with extracellular amyloid-β plaques deposit appears the earliest and followed by intracellular phosphorylated tau deposition and downstream neurodegeneration events ([@bb0155]). Hence, combining the pathological stages with the symptomatic diagnosis can help to assess AD continuum more accurately ([@bb0245]).

Spatially, AD neuropathological deposition around neurons impairs synaptic communication, resulting in neuronal networks disorganization ([@bb0255]). As such, AD is regarded as a disconnection disease featuring intrinsic network disorganization ([@bb0095]). The most commonly affected brain regions in AD studies are the default mode network (DMN), salience network (SN) and executive control network (ECN), which cooperate to maintain cognitive abilities including memory, and executive function ([@bb0385]; [@bb0295]). Notably, recent studies also reported that the DMN consists of multiple, spatially dissociated but interactive subsystems, including the midline core subsystem (self-relevant decision-making) and medial temporal subsystem (episodic memory) ([@bb0030]; [@bb0350]). Moreover, these network disruptions have been associated with cognitive dysfunction in AD. Therefore, brain network analysis could be an effective method to study AD neuropathology and explore further cognitive changes.

Brain networks can be constructed based on similarity in GM structure between brain areas, which was named as the gray matter (GM) structural covariance network (SCN) ([@bb0230]; [@bb0015]; [@bb0345]). Based on prior studies, the biological meaning of SCN may link to coordinated GM growth during development ([@bb0015]), functional co-activation ([@bb0020]), axonal connectivity ([@bb0115]; [@bb0135]) and genetic factors ([@bb0090]; [@bb0285]; [@bb0010]). Brain areas that are highly correlated in size are always part of systems that subserving specific behavioral or cognitive functions ([@bb0015]; [@bb0390]). For example, areas involved in memory showed GM volume covariance ([@bb0055]). In AD, SCN showed disorganization which correlates with cognitive dysfunction ([@bb0100]; [@bb0340]). Specifically, Spreng et al. demonstrated decreased SCN in DMN in AD patients ([@bb0325]). Another SCN study showed that early AD patients had decreased structural association within the DMN while increased structural association in the SN and ECN ([@bb0250]). These results indicate the trend of decreased structural association in DMN while increased structural association in ECN and SN in AD patients. However, few studies considered the AD neuropathological stages. This may lead to inaccurate results considering the temporal-ordered neuropathological propagation along the network.

To address this gap, the current study aimed to explore the trajectory of SCN changes along the pathophysiological continuum of AD. Combining the neuropathological hallmarks and symptomatic status, we classified the subjects into four groups to reflect the disease progression along the AD continuum. According to the evidence that AD network highly linked to its neuropathological state ([@bb0300]; [@bb0180]), we hypothesized that DMN tends to show a decreased structural association while the ECN and SN tend to show an increased structural association as AD progresses.

2. Methods and materials {#s0010}
========================

2.1. Alzheimer\'s disease neuroimaging and initiative {#s0015}
-----------------------------------------------------

Data used in the preparation of this article were obtained from the Alzheimer\'s disease Neuroimaging Initiative (ADNI) database (<http://adni.loni.usc.edu>). The ADNI was initially launched in 2004 (ADNI-1), and additional recruitment was made through ADNI-GO in 2009, ADNI-2 in 2010 and ADNI-3 in 2016. The primary goal of ADNI has been to identify serial MRI, PET, biomarkers and genetic characteristics that would support the early detection and tracking of the AD, and improved clinical trial design. For up-to-date information, see <http://www.adni-info.org>.

2.2. Study participants {#s0020}
-----------------------

This study was approved by the Institutional Review Boards of all participating institutions and informed written consent was obtained from all participants at each site. Similar to the previous study ([@bb0260]), we identified 242 non-demented subjects (characterized as either cognitively unimpaired or mild cognitive impairment, MCI) and 91 demented subjects from ADNI database ([Table 1](#t0005){ref-type="table"}, the flowchart in Supplementary Material 1). We included MCI subjects since the cognitive impairment may be not caused by an underlying AD process and, given that about a third of MCI were incorrectly diagnosed ([@bb0035]; [@bb0105]). Furthermore, based on the pathological system ([@bb0165]), we identified demented subjects in the study since the Alzheimer\'s disease with dementia features the highest risk of clinical progression and can present the most classic AD-related changes.Table 1Demographic and neuropsychological data in subjects along the AD continuum.Table 1Demographic characteristicsGroup 0\
*N* = 101Group 1\
*N* = 40Group 2\
N = 101Group 3\
*N* = 91*P*-valueAge,y, mean (SD)71.40 ± 6.2972.70 ± 7.0172.68 ± 5.7073.34 ± 7.76G1-G0 = 0.29G2-G0 = 0.13G3-G0 = 0.06Female, n(%)51(50.50%)14(35.00%)45(44.55%)41(45.05%)G1-G0 = 0.07G2-G0 = 0.24G3-G0 = 0.27Education,y, mean (SD)16.42 ± 2.6616.38 ± 2.6116.36 ± 2.4015.80 ± 2.45G1-G0 = 0.93G2-G0 = 0.87G3-G0 = 0.10APOE ε4 status, n(%)16(15.84%)15(37.50%)61(60.39%)67(73.63%)G1-G0 = 0.01[⁎](#tf0005){ref-type="table-fn"}G2-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}G3-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}GDS1.30 ± 1.421.43 ± 1.551.50 ± 1.591.64 ± 1.38G1-G0 = 0.64G2-G0 = 0.35G3-G0 = 0.09  General mental statusMMSE28.77 ± 1.3828.80 ± 1.2728.17 ± 1.7323.00 ± 2.30G1-G0 = 0.91G2-G0 = 0.01[⁎](#tf0005){ref-type="table-fn"}G3-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}CDR global0.30 ± 0.250.26 ± 0.250.36 ± 0.220.80 ± 0.28G1-G0 = 0.40G2-G0 = 0.08G3-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}CDR sum0.79 ± 0.820.73 ± 0.911.18 ± 1.114.63 ± 1.80G1-G0 = 0.71G2-G0 = 0.01[⁎](#tf0005){ref-type="table-fn"}G3-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}  Memory functionWMS-LM immediate12.76 ± 3.2013.18 ± 3.3711.04 ± 4.213.93 ± 2.49G1-G0 = 0.51G2-G0 = 0.001[⁎](#tf0005){ref-type="table-fn"}G3-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}WMS-LM delay10.87 ± 3.4411.65 ± 3.769.04 ± 4.641.47 ± 1.70G1-G0 = 0.24G2-G0 = 0.002[⁎](#tf0005){ref-type="table-fn"}G3-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}AVLT sum of trials 1--544.71 ± 11.6441.75 ± 11.0837.28 ± 10.6321.96 ± 7.42G1-G0 = 0.169G2-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}G3-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}AVLT 30 min7.19 ± 4.046.60 ± 3.804.33 ± 3.920.51 ± 1.07G1-G0 = 0.43G2-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}G3-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}  AttentionLog-transformed TMT-A1.51 ± 0.141.54 ± 0.161.55 ± 0.141.71 ± 0.21G1-G0 = 0.34G2-G0 = 0.12G3-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}  Decision-making functionLog-transformed TMT-B1.90 ± 0.181.94 ± 0.191.95 ± 0.202.23 ± 0.21G1-G0 = 0.27G2-G0 = 0.08G3-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}  LanguageBNT total27.71 ± 2.6227.68 ± 2.2627.73 ± 2.9621.67 ± 6.00G1-G0 = 0.93G2-G0 = 0.96G3-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}Category fluency19.59 ± 5.1018.35 ± 5.8319.26 ± 5.3611.70 ± 4.89G1-G0 = 0.22G2-G0 = 0.65G3-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}  Visuospatial processingCDT4.59 ± 0.674.43 ± 0.714.57 ± 0.353.49 ± 1.45G1-G0 = 0.19G2-G0 = 0.84G3-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}  CSFAβ~1--42~ (pg/ml)228.93 ± 23.66159.92 ± 26.80136.75 ± 25.24126.71 ± 20.74G1-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}G2-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}G3-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}T-Tau(pg/ml)43.45 ± 13.6441.64 ± 13.4396.30 ± 41.18143.90 ± 67.02G1-G0 = 0.47G2-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}G3-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}P-Tau~181~(pg/ml)17.40 ± 3.7817.54 ± 3.8149.77 ± 15.1165.29 ± 34.24G1-G0 = 0.84G2-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}G3-G0 \< 0.001[⁎](#tf0005){ref-type="table-fn"}[^2][^3][^4]

Cognitively unimpaired subject was defined as having a Clinical Dementia Rating scale (CDR) score of 0, an Mini-Mental State Examination (MMSE) between 24 and 30 (inclusive), a normal Wechsler Memory Scale Logical Memory, WMS-LM, delay recall performance (in detail: ≥ 9 for subjects with 16 or more years of education; ≥ 5 for subjects with 8--15 years of education; and ≥ 3 for 0--7 years of education); absence of clinical depression (geriatric depression scale-15, GDS-15 score \< 6) ([@bb0315]) and absence of dementia. MCI ([@bb0060]) was defined as having preserved activities of daily living, the absence of dementia, and objective cognitive impairment as shown on the delayed recall test of the WMS-LM as well as a CDR score of 0.5. Demented individuals were defined as having an MMSE score of ≤26, and a clinical dementia rating (CDR) of ≥0.5 as well as satisfying the NINCDS/ADRDA criteria for probable AD ([@bb0225]). We excluded subjects with the following manifestations: (a) significant medical, neurological, and psychiatric illness; (b) obvious head trauma history; (c) use of non-AD-related medication known to influence cerebral function; (d) clinical depression; (e) alcohol or drug abuse. Only subjects with a simultaneous structural scan, lumbar puncture, and comprehensive neuropsychological assessments were included.

2.3. Neuropsychological assessment and CSF data acquisition {#s0025}
-----------------------------------------------------------

All subjects underwent comprehensive neuropsychological tests ([Table 1](#t0005){ref-type="table"}, description about demographics in Supplementary Material 2), including assessment of general mental status (Mini-Mental State Examination, MMSE; Clinical Dementia Rating, CDR) and other cognitive domains, involving memory function (Auditory Verbal Learning Test, AVLT; WMS-LM, immediate and delayed memory), attention (Trail-Making Test part A, TMT-A), visuospatial function (Clock-Drawing Test, CDT), decision-making function (Trail-Making Test part B, TMT-B), and language ability (Boston Naming Test, BNT; Category fluency).

CSF biomarkers comprise amyloid-beta~1--42~ (Aβ~1--42~), total tau (T-tau), and phosphorylated tau at position~181~ (P-tau~181~), measured by the multiplex xMAP Luminex platform as previously described ([@bb0310]) ([Table 1](#t0005){ref-type="table"}).

2.4. Group classifications {#s0030}
--------------------------

We combined the latest pathological classification model ([@bb0165]) with the symptomatic diagnosis to reflect the disease progression along the AD continuum. Specifically, this model uses three major neuropathological biomarkers: amyloid deposition (A), pathologic tau (T), and neurodegeneration (N) \[AT(N)\] to stage the disease pathology across entire AD continuum in vivo (Supplementary Material 3). As previous studies described, we set the CSF cutoff point at 192 pg/ml for Aβ~1--42~ and 23 pg/ml for P-tau~181~ ([@bb0310]; [@bb0235]). Subsequently, based on the pathological AT(N) system, we classified all subjects into four groups according to their CSF Aβ~1--42~ and P-tau~181~ level: (a) Group 0: subjects with normal AD biomarkers, consisting of non-demented individuals with normal Aβ~1--42~ and P-tau~181~ (A − T−); (b) Group 1: subjects with Alzheimer\'s pathologic change, consisting of non-demented individuals with abnormal Aβ~1--42~ and normal P-tau~181~ (A + T−); (c) Group 2: subjects with biological Alzheimer\'s disease, consisting of non-demented individuals with abnormal Aβ~1--42~ and P-tau~181~ (A + T+); (d) Group 3: Alzheimer\'s disease with dementia, consisting of demented subjects with abnormal Aβ~1--42~ and P-tau~181~ (A + T+). Notably, we excluded subjects with normal Aβ~1--42~ and abnormal P-tau~181~ (A-T+) since it was considered as a non-AD related pathology ([@bb0160]).

2.5. MRI acquisition and pre-processing {#s0035}
---------------------------------------

MRI data were acquired in 3 T scanners. Briefly, the ADNI protocol includes T1-weighted acquisition based on a sagittal volumetric magnetization-prepared rapid gradient echo sequence collected from a variety of MR systems with protocols optimized for each type of scanner. Representative imaging parameters were as follows: repetition time (TR) =2300 ms; echo time (TE) =3 ms; within plane FOV = 256 × 256 mm^2^; voxel size = 1.1 × 1.1 × 1.2 mm^3^; flip angle = 9° or 11°.

We pre-processed all T1-weighted images using the Computational Anatomy Toolbox (CAT12, <http://dbm.neuro.uni-jena.de/cat12/>) toolbox segment data pipeline implemented within SPM12 in Matlab (R2012b). First, the T1 image was spatially registered to the tissue probability maps (TPM) and then segmented into gray matter (GM), white matter (WM) and cerebrospinal fluid (CSF). We performed the affine registration to the stereotactic MNI space using ICBM152 space. Second, we performed high-dimensional DARTEL normalization and nonlinear modulation using the Jacobian determinants derived from the normalization process. To remove the MRI inhomogeneities and noise, we corrected the bias, noise and normalized the intensities. Subsequently, we smoothed the GM image with a Gaussian kernel of 8 × 8 × 8 mm^3^ to reduce potential inaccuracies during the normalization step. Moreover, we assessed processed image quality by visual inspection and weighted average image quality index (using the quality assurance (QA) framework in CAT 12, <http://www.neuro.uni-jena.de/cat/>). Here, we only include the subjects with QA better than C+. Finally, 64 subjects did not pass the image quality control.

2.6. Structural covariance gray matter network {#s0040}
----------------------------------------------

To construct the SCNs, we chose four regions of interest (ROIs) ([@bb0250]): right entorhinal cortex (EC, MNI coordinates: 25, −9, −28) ([@bb0045]; [@bb0110]), left posterior cingulate cortex (PCC, MNI coordinates: −2, −36, 35) ([@bb0325]; [@bb0395]), right frontoinsular cortex (FIC, MNI coordinates: 38, 26, −10), and right dorsolateral prefrontal cortex (DLPFC, MNI coordinates: 44, 36, 20) ([@bb0390]; [@bb0250]). These regions anchor the default mode network (DMN, medial temporal subsystem), DMN (midline core subsystem), salience network (SN) and executive control network (ECN) respectively.

To achieve SCN t-maps, we performed the general linear analysis on modulated GM images. Specifically, we extracted the GM volume from a 4-mm radius sphere ([@bb0250]; [@bb0085]; [@bb0080]) around those coordinates on modulated images. Then, we performed four separate correlation analysis by entering the GM volumes of each ROI as a regressor and the total intracranial volume, gender, age, and education as covariates. Before statistical correction, we performed Fisher\'s Z transformation. For each group, we performed specific contrasts to identify voxels expressing a positive correlation with each ROI. We set the threshold at *P* ≤ 0.01 corrected for false discovery rate (FDR). Considering the physiological meanings of the SCN clusters, we reported clusters showing cluster size \>100 voxels ([@bb0085]; [@bb0080]). To achieve qualitative group-wise comparisons, we displayed the results on a standard brain template (ICBM152).

Then, we used multi-regression model-based linear interaction analysis ([@bb0045]) to assess how the disease stage interferes with SCN, voxels showing significant differences in the regression slopes in each ROI were compared. For this study, we refer to these differences in slopes as the differences in "structural association". We set the threshold at *p* \< 0.05 at voxel level, p \< 0.05 at cluster level, with Gaussian random field correction (GRF) corrected.

To explore the clinical significance of the identified peak voxel volume, we performed the correlation analysis ([@bb0085]; [@bb0080]). To be specific, for the peak clusters showing significant between-group differences, we extracted the GM volume using a 4-mm radius sphere placing on the peak voxel. Then, we conducted Pearson correlation analysis between the peak voxel volume and neuropsychological data within each group which showed the difference in the structural association. The threshold was set at p \< 0.05, Bonferroni corrected.

3. Results {#s0045}
==========

3.1. Patterns of structural association within each group {#s0050}
---------------------------------------------------------

To qualitatively compare the patterns of positive correlations in subjects at all groups, we presented the statistical maps in [Fig. 1](#f0005){ref-type="fig"}. Regions presenting a structural association with the seed regions of each network in each group are listed in supplementary material 4.Fig. 1Patterns of structural association within Group.(A) the target seeds; (B) structural covariance networks (*Z*-statistic maps \[*p* \< 0.01, corrected with a false discovery rate with extended cluster voxels \>100\]). All the results were projected on a standard brain template.Abbreviations: R: Right; L: left; DMN: default mode network; SN: salience network; ECN: executive control network; EC: entorhinal cortex; PCC: posterior cingulate cortex; FIC: frontoinsular cortex; DLPFC: dorsolateral prefrontal cortex; Group 0: subjects with normal AD biomarkers, non-demented individuals without abnormal CSF; Group 1: subjects with Alzheimer\'s pathologic change, non-demented individuals with abnormal Aβ~1--42~ but normal P-tau~181~; Group 2: subjects with biological Alzheimer\'s disease, non-demented individuals with abnormal Aβ~1--42~ and P-tau~181~; Group 3: Alzheimer\'s disease with dementia, demented individuals with abnormal Aβ~1--42~ and P-tau~181~.Fig. 1

In both DMN midline core subsystem and ECN, the subjects in Group 3 presents a greater extent of structural covariance than Group 0; In both DMN medial temporal subsystem and SN, the subjects in Group 3 presents a decreased extent of structural covariance than Group 0.

3.2. VThe difference of structural covariance gray matter network {#s0055}
-----------------------------------------------------------------

Regarding DMN medial temporal subsystem, subjects in Group 2 showed an increased structural association between the EC and middle temporal gyrus (MTG); subjects in Group 3 showed a decreased structural association between the EC and MTG as well as superior frontal gyrus (SFG) compared to subjects in Group 0. Regarding the DMN midline core subsystem, no significant difference existed in Group 1, 2, or 3 compared to Group 0. Regarding SN, subjects in Group 1 showed an increased structural association between FIC and precuneus; as pathological accumulation progressed, subjects in Group 3 showed the decreased structural association between FIC and the inferior temporal gyrus. Regarding ECN, subjects in Group 1 and Group 3 showed an increased structural association between DLPFC and SFG ([Fig. 2](#f0010){ref-type="fig"} and [Table 2](#t0010){ref-type="table"}). Moreover, to qualitatively depict the SCNs pattern, we also performed the group difference analysis between Group 1, 2, and 3 (Supplementary Material 8).Fig. 2The difference of Gray Matter Structural Covariance network between subjects in AD continuum and Group 0.(A) As for DMN medial temporal subsystem, subjects in Group 2 showed an increased structural association between the EC and MTG; subjects in Group 3 showed a decreased structural association between the EC and MTG as well as SFG when compared to subjects in Group 0. (B) As for SN, subjects in Group 1 showed an increased structural association between FIC and precuneus; subjects in Group 3 showed decreased association between FIC and the inferior temporal gyrus. (C) As for ECN, subjects in Group 1 in Group 3 showed an increased structural association in the SFG.Abbreviations: DMN: default mode network; SN: salience network; ECN: executive control network; EC: entorhinal cortex; FIC: frontoinsular cortex; DLPFC: dorsolateral prefrontal cortex; MTG: middle temporal gyrus; SFG: superior frontal gyrus; Group 0: subjects with normal AD biomarkers, non-demented individuals without abnormal CSF; Group 1: subjects with Alzheimer\'s pathologic change non-demented individuals with abnormal Aβ~1--42~ but normal P-tau~181~; Group 2: subjects with biological Alzheimer\'s disease, non-demented individuals with abnormal Aβ~1--42~ and P-tau~181~; Group 3: Alzheimer\'s disease with dementia, demented individuals with abnormal Aβ~1--42~ and P-tau~181~.Fig. 2Table 2The difference of gray matter structural covariance network between subjects in AD continuum and Group 0.Table 2NetworkGroupPeak regionMNI coordinatesExtentPeak intensityXYZDefault mode (medial temporal lobe subsystem) (R EC)Group 2 VS. Group 0L Middle Temporal Gyrus−49.5−19.5−4.588114.81Group 3 VS. Group 0L Middle Temporal Gyrus−454.5−31.59380−4.25L Superior Frontal Gyrus1236366031−3.80Salience (R FIC)Group 1 VS. Group 0L Precuneus−12−58.53639923.80Group 3 VS. Group 0L Inferior Temporal Gyrus−55.5−33−22.54167−4.24Executive Control (R DLPFC)Group 1 VS. Group 0R Superior Frontal Gyrus12273632083.85Group 3 VS. Group 0R Superior Frontal Gyrus18655.599774.50[^5]

Additionally, we performed an analysis using the contralateral ROI seeds by changing the sign on each seed\'s x coordinate ([@bb0390]). DMN showed initially increased and then decreased structural association between EC and frontal region along AD continuum. SN showed the increased structural association between FIC and inferior parietal gyrus at the early neuropathological stage (Supplementary Material 5).

To test the reliability, we adopted different statistical thresholds. Results remained mostly unchanged (Supplementary Material 6). Moreover, we repeated the analysis based on ADNI1 database (acquired from 1.5 T MRI scanner). Similarly, DMN showed a trend of the decreased structural association while ECN showed a trend of increased structural association (Supplementary Material 7).

3.3. Correlations of peak cluster volumes with neuropsychological scores {#s0060}
------------------------------------------------------------------------

We then performed the Pearson correlation analysis between the peak cluster volumes and neuropsychological scores. The correlation mainly located at the EC anchored DMN medial temporal subsystem, concerning memory and language ([Table 3](#t0015){ref-type="table"}). To be specific, in Group 3 subjects, the peak volume of MTG significantly correlated with memory (WMS-LM immediate and delay (*r* = 0.34, *p* \< 0.005, *r* = 0.30, p \< 0.005, respectively); AVLT sum of trials 1--5 (r = 0.34, p \< 0.005)), language (category fluency (*r* = 0.42, *p* \< 0.001), BNT total (*r* = 0.39, p \< 0.001)), and executive function (log-transformed TMT-B (*r* = −0.33, p \< 0.005)). Moreover, regarding DLPFC anchored ECN, in Group 3 subjects, the peak volume of SFG negatively correlated with log-transformed TMT-A (*r* = −0.35, p \< 0.005) and log-transformed TMT-B (*r* = −0.48, p \< 0.001).Table 3Correlation coefficients between peak cluster volume and neuropsychological data.Table 3Seed regionEC (25, −9, −28)DLPFC (44, 36, 20)FIC (38, 26, −10)Peak ClusterMTG (G0 \< G2)MTG (G0 \> G3)SFG (G0 \> G3)SFG (G0 \< G1)SFG (G0 \< G3)precuneus (G0 \< G1)ITG (G0 \> G3)GroupG0G2G0G3G0G3G0G1G0G3G0G1G0G3  General cognitive stateMMSE0.06**0.30a**0.07**0.21**0.110.030.08**0.38**−0.360.140.190.220.04**0.26**CDR global0.16**−0.22**−0.04**−0.23**0.08−0.020.09−0.070.04−0.040.18−0.130.14**−0.21**CDR sum0.10**−0.30a**−0.06**−0.23**−0.06−0.100.02−0.010.020.060.10−0.170.04−0.19  MemoryWMS-LM immediate−0.030.19**0.220.34b**−0.02**0.21**−0.050.030.05**0.25**−0.140.000.10**0.22**WMS-LM delay−0.01**0.240.210.30a**0.050.010.010.160.010.07−0.170.110.030.21AVLT sum of trials 1--5−0.07**0.21**0.00**0.34b**0.050.120.170.27**−0.21**0.120.030.16−0.140.16AVLT 30 min−0.030.170.06**0.33b**0.130.020.160.24−0.160.09−0.050.03−0.12**0.22**  LanguageBNT total0.10**0.29a0.38b0.39b0.21**0.040.190.050.070.14**0.23**−0.16**0.36b**0.21Category fluency0.20**0.35b0.29a0.42b0.30a**0.09**0.36b0.41**0.130.11**0.200.320.220.35b**Attention  Log-transformed TMT-A−0.18−0.12**−0.26**−0.17−0.19−0.13−0.10−0.19−0.01**−0.35b**−0.12−0.02−0.11−0.10  Decision-making functionLog-transformed TMT-B−0.09**−0.30a**−0.19**−0.33a**−0.07−0.22−0.11−0.190.02**−0.48b**−0.14−0.07−0.13**−0.33a**  Visual-spacial processingCDT−0.120.15−0.02**0.27**−0.090.100.03**0.38**0.0040.16−0.120.16−0.03**0.25**[^6][^7]

4. Discussion {#s0065}
=============

Our study explored the SCN changes along the AD continuum based on the neuropathological classification system. Regarding the DMN and SN, subjects at the early and late stage of AD successively showed increased and decreased structural association. As for ECN, subjects with abnormal CSF showed progressively increased structural association as AD neuropathological profiles progress. Our results suggest the dynamic trajectory of AD progression based on GM SCN technique and provide support for the disconnection hypothesis underlying AD neuropathological progression.

These results are partially in line with previous studies which reported the DMN, SN ([@bb0335]; [@bb0375]) and the ECN changes ([@bb0360]; [@bb0005]) in AD by using the functional ([@bb0375]; [@bb0065]; [@bb0200]; [@bb0205]) or white matter connectivity analysis ([@bb0125]). The possible mechanism is the high metabolic load in DMN ([@bb0070]) and pathogenic molecules spread via synaptic connections ([@bb0380]; [@bb0275]; [@bb0185]; [@bb0175]; [@bb0240]; [@bb0270]). Although SCN could not be considered as a direct measure of connectivity, convergent studies reported the spatial overlap between intrinsic connectivity and structural covariance, thus demonstrating that these patterns mirror each other ([@bb0230]; [@bb0300]; [@bb0305]; [@bb0370]; [@bb0190]). This could be explained by the fact that synchronous neuronal firing promotes network based synaptogenesis ([@bb0170]; [@bb0050]). Accordingly, GM SCN could indicate the connectivity to some extent and provide additional insight into the network topographical organization ([@bb0015]; [@bb0040]; [@bb0140]). Here, decreased correlations between brain regions may be suggestive of disconnectivity or localization degeneration while increased correlations may indicate overconnectivity or correlated gray matter loss in regions targeted by the same neurodegenerative process.

Regarding the DMN, subjects at the early stage of AD showed increased structural association while decreased association in subjects at the late stage. This result is in line with previous studies which reported the early involvement of DMN in AD ([@bb0300]; [@bb0150]; [@bb0210]; [@bb0215]; [@bb0130]), and the progressive SCN DMN score decline through the AD progression ([@bb0325]). The mechanism may be the activity-dependent or metabolism-dependent pathology hypothesis: the DMN\'s continuous activity may lead to the early formation and diffusion of the AD neuropathological hallmarks ([@bb0260]; [@bb0070]; [@bb0075]). To be specific, we found an increased structural association between the EC and MTG in Group 2 and decreased structural association between EC and MTG as well as SFG in Group 3. Although no significant difference in Group 1, these subjects show the trend of an increased structural association involving the temporal and frontal regions. These changes could be described as a biphasic trajectory which was resulted by neuropathological progression. Moreover, such DMN changes always correlate with cognitive status and CSF level ([@bb0325]; [@bb0025]; [@bb0365]). One SCN study found a decreased association between EC and prefrontal region in early AD patients and proposed it as the underlying reason for cognitive deficits ([@bb0250]). Similarly, we also found that entorhinal-anchored peak clusters linked to the clinical scores in the subjects along the AD continuum. These findings highlighted the primary role of the entorhinal-anchored network (DMN medial temporal subsystem) in cognition maintenance. Conclusively, we proposed that DMN showed a structural hyperconnectivity at the early stage and then hypoconnectivity as AD progresses; furthermore, structural connectivity changes may indicate the cognition decline.

SN is in charge of diverse homeostatically relevant internal and external stimuli, and always shows alternated function in AD patients. Here, we observed a dynamic structural association in this intrinsic network: increased structural association between FIC and precuneus in Group 1 subjects, while decreased structural association in ITG in Group 3 subjects. These results are in line with one functional study, which reported firstly increased (between CDR 0 and CDR 0.5) and then decreased correlation (at CDR 1) in SN in subjects along AD continuum ([@bb0065]). Similarly, the work of Schultz AP also reported hyperconnectivity in SN in subjects with amyloid positive and then hypoconnectivity when neocortical tau levels are high ([@bb0290]). Conclusively, these findings suggested the dynamic changes in SN along AD neuropathological progression.

Regarding the ECN, we observed a continuously increased association in Group 1 and Group 3 subjects. Based on the previous study, we speculated it as a compensatory network associated with cognitive reservation in AD patients ([@bb0145]; [@bb0330]). Similar results can be found in another study which observed extensive SCN in ECN in AD patients with positive Aβ status ([@bb0250]). Our data extended this work by demonstrating a gradually increased structural association between DLPFC and frontal regions along the AD continuum. Here, stronger covariance strength between the seed and peak clusters indicated more intra-network connections to maintain cognition ([@bb0195]). Our further correlation analysis showed that DLPFC-anchored peak cluster volumes correlated to the cognitive performance, suggesting a compensatory clinical meaning of the DLPFC-anchored ECN in AD continuum. By coincidence, SFG presents a significant decreased structural association with the EC in AD patients. This may partially support the hypothesis that AD features opposing connectivity in the DMN and ECN ([@bb0375]; [@bb0005]).

The DMN, SN, and ECN showed interactive and dynamic changes with neuropathological progression. Regarding the increased structural association in DMN and SN at the early stage, possible explanations may be the compensatory processes in response to toxic effects of Aβ ([@bb0335]; [@bb0375]; [@bb0220]) or the amyloid-induced inflammatory response ([@bb0245]), especially in Group 1. Such inflammation would trigger changes in cell volume (neuronal and glia swelling) as well as number (glia recruitment and activation) at the early stages of AD pathology and lead to the GM volume changes ([@bb0120]; [@bb0280]). As the neuropathological progression, the synergy between amyloid and tau pathologies starts ([@bb0290]; [@bb0265]), such compensation mechanism become gradually invalid, ending with the whole structural connectivity in chaos. This could be proved the progressively decreased cognition in Group 2 and Group 3, reflecting the progressive decompensation process.

Conclusively, our study suggested a dynamic SCN pattern changes along the temporal pathological accumulation. As the AD progresses, the DMN and SN showed phases of hyperconnectivity and then hypoconnectivity while ECN showed the potentially compensatory role of the ECN in AD patients.

5. Limitation {#s0070}
=============

There were some limitations to this study. Firstly, our study is cross-sectional research. Although we try to use the subjects with different disease stages to depict the AD continuum, a further longitudinal study should be done. Moreover, our SCN analysis was constructed in a group level which may not allow the assessment of the relationship between single-subject gray matter network measures with cognition. Further SCN analysis based on single-subject should be done.
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[^1]: Data used in the preparation of this article were obtained from the Alzheimer\'s disease Neuroimaging Initiative (ADNI) database (<http://www.adni.loni.usc.edu>). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at <http://adni.loni.usc.edu/wp-content/up> loads/how to apply/ADNI Acknowledgement List.pdf.

[^2]: Data are presented as means ± standard deviations;

[^3]: Abbreviation: Group 0: G0, subjects with normal AD biomarkers, non-demented individuals without abnormal CSF; Group 1: G1, subjects with Alzheimer\'s pathologic change, non-demented individuals with abnormal Aβ~1--42~ but normal P-tau~181~; Group 2: G2, subjects with biological Alzheimer\'s disease, non-demented individuals with abnormal Aβ~1--42~ and P-tau~181~; Group 3: G3, Alzheimer\'s disease with dementia, demented individuals with abnormal Aβ~1--42~ and P-tau~181~; MMSE, Mini-Mental State Examination; CDR: Clinical Dementia Rating; WMS-LM, Wechsler memory scale-logical memory; AVLT, Auditory Verbal Learning Test; TMT, Trail-Making Test; BNT, Boston naming test; CDT, Clock Drawing Test.

[^4]: *p* \< 0.05, significant difference between the two Groups.

[^5]: Abbreviation: R: right; EC: entorhinal cortex; FIC: frontoinsular cortex; DLPFC: dorsolateral prefrontal cortex; Group 0: subjects with normal AD biomarkers, non-demented individuals without abnormal CSF; Group 1: subjects with Alzheimer\'s pathologic change, non-demented individuals with abnormal Aβ~1--42~ but normal P-tau~181~; Group 2: subjects with biological Alzheimer\'s disease, non-demented individuals with abnormal Aβ~1--42~ and P-tau~181~; Group 3: Alzheimer\'s disease with dementia, demented individuals with abnormal Aβ~1--42~ and P-tau~181~.

[^6]: Numbers indicate Pearson correlation coefficients, a: p \< .005, b: *p* \< .01.

[^7]: Abbreviation: EC: entorhinal cortex; DLPFC: dorsolateral prefrontal cortex; FIC: frontoinsular cortex; MTG: middle temporal gyrus; SFG: superior frontal gyrus; ITG: inferior temporal gyrus; Group 0: G0, subjects with normal AD biomarkers, non-demented individuals without abnormal CSF; Group 1: G1, subjects with Alzheimer\'s pathologic change, non-demented individuals with abnormal Aβ~1--42~ but normal P-tau~181~; Group 2: G2, subjects with biological Alzheimer\'s disease, non-demented individuals with abnormal Aβ~1--42~ and P-tau~181~; Group 3: G3, Alzheimer\'s disease with dementia, demented individuals with abnormal Aβ~1--42~ and P-tau~181.~ MMSE, Mini-Mental State Examination; CDR: Clinical Dementia Rating; WMS-LM, Wechsler memory scale-logical memory; AVLT, Auditory Verbal Learning Test; TMT, Trail-Making Test; BNT, Boston naming test; CDT, Clock Drawing Test.
